Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion

Journal of the American College of Cardiology

Volumn 28, Issue 1, 1996, Pages 247-252

  Gurevitch, Jacob ^a   Frolkis, Inna ^a   Yuhas, Yael ^b   Paz, Yosi ^a   Matsa, Menachem ^a   Mohr, Rephael ^a   Yakirevich, Vladimir ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEMODYNAMICS; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; REPERFUSION INJURY;

EID: 0030198549     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)00105-2     Document Type: Article

References (50)

1. 1. Beutler B, Cerami A. Cachectin more than a tumor necrosis factor. N Engl J Med 1987;316:379-85.
2. 2. Odeh M. Tumor necrosis factor-α as a myocardial depressant substance. Int J Cardiol 1993;42:231-8.
3. 3. Tracey KJ, Vlasara H, Cerami A. Cachectin/tumor necrosis factor. Lancet 1989;20:1122-6.
4. 4. Smith SC, Allen PM. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res 1992;70: 856-63.
5. 5. Arbustini E, Grasso M, Diegoli M, et al. Expression of tumor necrosis factor in human acute cardiac rejection: an immunohistochemical and immunoblotting study. Am J Pathol 1991;139:709-15.
6. 6. Maury CPJ, Teppo AM. Circulating tumor necrosis factor-α (cachectin) in myocardial infarction. J Intern Med 1989;225:333-6.
7. 7. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;223:236-41.
8. 8. Jansen JN, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. Endotoxin release and tumor necrosis factor formation during cardio-pulmonary bypass. Ann Thorac Surg 1992;54:744-8.
9. 9. Laidler J, Paes ML, Wheeler J, Freeman R, Robertson H. Detection of circulating tumor necrosis factor-α after elective cardiopulmonary bypass. Perfusion 1991;6:51-4.
10. 10. Squadrito F, Altavilla D, Zingarelli B, et al. Tumor necrosis factor involvement in myocardial ischaemia-reperfusion injury. Eur J Pharmacol 1993;237: 223-30.
11. 11. Luccesi BR. Modulation of leukocyte-mediated myocardial reperfusion injury. Ann Rev Physiol 1990;52:561-76.
12. 12. Dinerman JL, Mehta JL. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance. J Am Coll Cardiol 1991;17:1445-6.
13. 13. Matthews N, Naele ML, Jackson SK, Stark JM. Tumor killing by tumor necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology 1987;62:153-5.
14. 14. Yamuchi N, Kuriyama H, Watanabe N, Neda H, Maeda M, Niitsu Y. Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res 1989;49:1671-5.
15. 15. Zimmerman RJ, Chan A, Leadon SA. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 1989;49:1644-8.
16. 16. Pober JS, Cotran R. The role of endothelial cells in inflammation. Transplantation 1990;50:537-44.
17. 17. Casey WF, Hauster GJ, Hannallah RS, Midgley FM, Khan WN. Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgery. Crit Care Med 1992;20:1090-6.
18. 18. Hearse DJ, Stewart DA, Braimbridge MV. Cellular protection during myocardial ischaemia. Circulation 1976;54:193-202.
19. 19. Gurevitch J, Barak J, Hochhauser E, Paz Y, Yakirevich V. Aprotinin improves myocardial recovery following ischemia and reperfusion. J Thorac Cardiovasc Surg 1994;108:109-18.
20. 20. Young DS, Pestaner LC, Gibberman V. Effects of drugs on clinical laboratory tests. Clin Chem 1975;21:4310-20.
21. 21. Wallach D. Preparations of lymphotoxin induce resistance and their own cytotoxic effect. J Immunol 1984;132:2464-9.
22. 22. Yuhas Y, Shemer I, Sarov I, Wallach D. Protection of cells from TNF-α cytotoxicity by tryptophan and indole. Eur Cytokine Netw 1990;1:35-40.
23. 23. Neely JR, Liebermeister H, Battersby EJ, Morgan HE. Effects of pressure development on oxygen consumption by isolated rat hearts. Am J Physiol 1967;212:804-14.
24. 24. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995;96:1042-52.
25. 25. Tracey KJ, Beutler B, Lowrey SF, et al. Shock and tissue injury induced by recombinant human cachectin, Science 1986;229:869-71.
26. 26. Oliff A, Defeo-Jones D, Boyer M, et al. Tumor secreting human tumor necrosis factor-α/cachectin induce cachectia in mice. Cell 1987;50:555-63.
27. 27. Beutler B, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 1986;320:584-8.
28. 28. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
29. 29. Squadrito F, Altavilla D, Ioculano M, et al. Passive immunization with antibodies against tumor necrosis factor (tumor necrosis factor-α) protects from the lethality of splanchnic artery occlusion shock. Circ Shock 1992;37: 236-44.
30. 30. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbel DA Jr. Role of tumor necrosis factor-α in the pathophysiologic alterations after hepatic ischemia/reperfusion in the rat. J Clin Invest 1990;85:1936-43.
31. 31. Caputi AP, Squadrito F. Role of tumor necrosis factor-α and therapeutic perspectives in bowel and myocardial ischemia reperfusion injury. Pharmacol Res 1992;26 Suppl 2:150-1.
32. 32. Ikeda U, Ikeda M, Kano S, Shimada K. Neutrophil adherence to rat cardiac myocyte by proinflammatory cytokines. J Cardiovasc Pharmacol 1994;23: 647-52.
33. 33. Kukielka GL, Hawkins HK, Michael L, et al. Regulation of intracellular adhesion molecule-1 (ICAM-1) in ischemic and reperfused canine myocardium. J Clin Invest 1993;92:1504-16.
34. 34. Youker KA, Hawkins HK, Kukielka GL, et al. Molecular evidence for induction of intracellular adhesion molecule-1 (ICAM-1) in the viable border zone associated with ischemia-reperfusion injury of the dog heart. Circulation 1994;89:2736-46.
35. 35. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael L, Entman ML. Induction of interleukin-6 synthesis in the myocardium. Potential role in postperfusion inflammatory injury. Circulation 1995;92:1866-75.
36. 36. Feuerstein G. Leukotrienes and the cardiovascular system. Prostaglandins 1984;27:781-802.
37. 37. Lefer AM, Darius H. A pharmacological approach to thromboxane receptor antagonism. Fed Proc 1987;46:144-8.
38. 38. Bracquet P, Touqui L, Shen TY, Vargaftig GG. Perspectives in platelet-activating factor research. Pharmacol Rev 1987;39:97-105.
39. 39. Vane JR, Vasara H, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
40. 40. Munro JM, Pober JS, Cotran RS. TNF-α and IFN-α induced distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol 1989;135:121-33.
41. 41. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992;90:693-8.
42. 42. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995;146:419-28.
43. 43. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321: 280-7.
44. 44. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993;92:2303-12.
45. 45. Murphy HS, Shayman JA, Till GO, et al. Superoxide responses of endothelial cells to C5a and TNF: divergent signal transduction pathways. Am J Physiol 1992;263:L51-9.
46. 46. Pogrebniak HW, Matthews WA, Pass HI. Reactive oxygen species can amplify macrophage tumor necrosis factor production. Surg Forum 1990;16: 101-3.
47. 47. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
48. 48. Brady AJB, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992;263:H1963-6.
49. 49. Lamas S, Michel T, Brenner BM, Marsden PA. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF. Am J Physiol 1991;261:C634-41.
50. 50. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990;257:87-90.